Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven diagnosis of unresectable B3 thymoma or thymic carcinoma recurrent or progressing after prior chemotherapy (only one prior systemic therapy allowed)~* Presence of measurable disease~* Age \>=18 years~* ECOG performance status 0-1~* Negative pregnancy test (if female in reproductive years)~* Use of effective contraceptive methods if men and women of child producing potential~* Adequate liver function Total Serum Bilirubin \<=1.5 x upper limit of normal (ULN) Transaminases (AST/ALT) \<=2.5ULN (if liver metastases are present, then \<=5ULN is allowed) ALP \<=2.5ULN (if liver and/or bone metastases are present, then \<=5ULN is allowed)~* Adequate renal function Serum Creatinine \<=ULN or Creatinine Clearance calculated by Cockcroft and Gault's formula \> 60 mL/min.~* Adequate hematologic status ANC \>=1,500cells/mm3 Platelet Count \>=100,000cells/mm3 Hemoglobin \>=9.0g/dL~* Two weeks must have elapsed since completion of prior chemotherapy, minor surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated)~* Resolution of all acute toxic effects of any prior treatments to NCI CTC (Version 3.0) grade \<=1~Exclusion Criteria:~* Any of the following in the past 6 months: myocardial infarction, uncontrolled cardiac arrhythmia, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis~* Grade \>1 retinopathy~* Known brain metastases~* Known active infections~* Pregnant or breast feeding women~* Diabetes mellitus uncontrolled~* Gastrointestinal disease that would impact on drug absorption~* Patients under treatment with anticoagulants or with coagulation disorders or with signs of hemorrhage at baseline~* Patients with previous history or current presence of neurological disorders, including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease and extra-pyramidal syndromes~* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that make the patient inappropriate for entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Milciclib Maleate (PHA-848125AC) (Type: EXPERIMENTAL): 100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).